AU2013344817B2 - Transmucosal delivery of tocotrienol - Google Patents

Transmucosal delivery of tocotrienol Download PDF

Info

Publication number
AU2013344817B2
AU2013344817B2 AU2013344817A AU2013344817A AU2013344817B2 AU 2013344817 B2 AU2013344817 B2 AU 2013344817B2 AU 2013344817 A AU2013344817 A AU 2013344817A AU 2013344817 A AU2013344817 A AU 2013344817A AU 2013344817 B2 AU2013344817 B2 AU 2013344817B2
Authority
AU
Australia
Prior art keywords
tocotrienol
tocopherol
administration
tocotrienols
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013344817A
Other languages
English (en)
Other versions
AU2013344817A1 (en
Inventor
Glenn Tong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invictus Biotechnology Pty Ltd
Original Assignee
Invictus Biotechnology Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904937A external-priority patent/AU2012904937A0/en
Application filed by Invictus Biotechnology Pty Ltd filed Critical Invictus Biotechnology Pty Ltd
Priority to AU2013344817A priority Critical patent/AU2013344817B2/en
Publication of AU2013344817A1 publication Critical patent/AU2013344817A1/en
Application granted granted Critical
Publication of AU2013344817B2 publication Critical patent/AU2013344817B2/en
Assigned to Invictus Biotechnology Pty Ltd reassignment Invictus Biotechnology Pty Ltd Request for Assignment Assignors: GORDAGEN PHARMACEUTICALS PTY LTD
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2013344817A 2012-11-13 2013-11-13 Transmucosal delivery of tocotrienol Active AU2013344817B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013344817A AU2013344817B2 (en) 2012-11-13 2013-11-13 Transmucosal delivery of tocotrienol

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AU2012904937A AU2012904937A0 (en) 2012-11-13 Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents
AUAU2012904937 2012-11-13
AU2012905406A AU2012905406A0 (en) 2012-12-11 Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents
AUAU2012905406 2012-12-11
PCT/AU2013/001310 WO2014075135A1 (en) 2012-11-13 2013-11-13 Transmucosal delivery of tocotrienol
AU2013344817A AU2013344817B2 (en) 2012-11-13 2013-11-13 Transmucosal delivery of tocotrienol

Publications (2)

Publication Number Publication Date
AU2013344817A1 AU2013344817A1 (en) 2015-02-12
AU2013344817B2 true AU2013344817B2 (en) 2015-09-17

Family

ID=50730398

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013344817A Active AU2013344817B2 (en) 2012-11-13 2013-11-13 Transmucosal delivery of tocotrienol

Country Status (22)

Country Link
US (2) US10675265B2 (cg-RX-API-DMAC7.html)
EP (1) EP2919777B1 (cg-RX-API-DMAC7.html)
JP (3) JP6460998B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150082109A (cg-RX-API-DMAC7.html)
CN (2) CN112451518B (cg-RX-API-DMAC7.html)
AU (1) AU2013344817B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015010703B1 (cg-RX-API-DMAC7.html)
CA (1) CA2891164C (cg-RX-API-DMAC7.html)
DK (1) DK2919777T3 (cg-RX-API-DMAC7.html)
ES (1) ES2778065T3 (cg-RX-API-DMAC7.html)
IL (1) IL238727A0 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN04006A (cg-RX-API-DMAC7.html)
MY (1) MY177940A (cg-RX-API-DMAC7.html)
NZ (1) NZ628963A (cg-RX-API-DMAC7.html)
PE (1) PE20151518A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015501048A1 (cg-RX-API-DMAC7.html)
PL (1) PL2919777T3 (cg-RX-API-DMAC7.html)
PT (1) PT2919777T (cg-RX-API-DMAC7.html)
RU (1) RU2015120181A (cg-RX-API-DMAC7.html)
SG (1) SG11201503640WA (cg-RX-API-DMAC7.html)
WO (1) WO2014075135A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201504191B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
PT2919777T (pt) * 2012-11-13 2020-03-30 Invictus Biotechnology Pty Ltd Distribuição transmucosa de tocotrienol
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
JP6989262B2 (ja) 2014-10-27 2022-01-05 アセコー インコーポレイテッド 皮下外来患者管理
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
WO2017025808A1 (en) * 2015-08-11 2017-02-16 Satoru Sugiyama System and method for improved blood circulation and maintaining mitochondrial energy production
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor
WO2019032685A1 (en) * 2017-08-08 2019-02-14 Robert John Petcavich FORMULATIONS FOR THE CONTRIBUTION OF TREHALOSE STIMULATING AUTOPHAGIA
EP4255417A4 (en) * 2020-12-04 2024-10-23 Invictus Biotechnology Pty Ltd. Transmucosal delivery of tocotrienols

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151348A1 (en) * 2009-06-25 2010-12-29 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
WO2011082355A1 (en) * 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
WO2011126998A1 (en) * 2010-04-06 2011-10-13 Edison Pharmaceuticals, Inc. Treatment of ataxia telangiectasia
WO2012068552A1 (en) * 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124086A1 (en) * 1991-11-22 1993-05-27 Ronald H. Lane Tocotrienols and tocotrienol-like compounds and methods for their use
JPH0892050A (ja) 1994-09-27 1996-04-09 Lion Corp 消臭剤及び口腔用組成物
JP4271742B2 (ja) 1997-08-07 2009-06-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 免疫機能改善剤
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
JP2001342133A (ja) 2000-03-31 2001-12-11 Eisai Co Ltd γ―トコトリエノール含有利尿剤
ES2346181T3 (es) 2000-03-31 2010-10-13 EISAI R&D MANAGEMENT CO., LTD. Uso de gamma-tocotrienol como diuretico.
JP2002037727A (ja) 2000-07-26 2002-02-06 Eisai Co Ltd 脂溶性薬物を配合した速崩性固形製剤及びその製造方法
JP4693140B2 (ja) 2000-10-06 2011-06-01 富士化学工業株式会社 トコトリエノール含有医薬用剤
JP4447198B2 (ja) 2001-02-08 2010-04-07 富士化学工業株式会社 トコトリエノールを有効成分とする血管新生阻害剤、細胞増殖阻害剤、管腔形成阻害剤及びｆｇｆ阻害剤並びに食品或いは食品添加物
US6608103B2 (en) 2001-02-08 2003-08-19 Fuji Chemical Industry Co., Ltd. Inhibitor for neovasculation, cell multiplication, lumen formation and FGF
ES2391215T3 (es) 2003-02-14 2012-11-22 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Protección contra la radiación mediante gamma tocotrienol, succinato de alfa-tocoferol o succinato de gamma-tocoferol
CA2521020C (en) 2003-04-10 2021-04-27 Barrie Tan Annatto extract compositions including tocotrienols and tocopherols and methods of use
US20050209315A1 (en) * 2004-03-20 2005-09-22 Papas Andreas M Bioavailable nutritional supplement and method of treatment of malabsorption
CA2567969A1 (en) * 2004-05-26 2005-12-08 Kgk Synergize Inc. Compositions comprising flavonoids and tocotrienols and methods thereof
CN1775289B (zh) 2004-11-15 2011-08-24 杭州赛诺菲民生健康药业有限公司 多维生素口腔崩解片制剂及其制备方法
WO2009121039A2 (en) 2008-03-28 2009-10-01 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
WO2009126866A2 (en) 2008-04-10 2009-10-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Delta-tocotrienol as a radioprotective countermeasure agent
EP2437730A4 (en) 2009-05-20 2014-02-26 Lingual Consegna Pty Ltd ORAL AND / OR SUBLINGUAL THERAPEUTIC FORMULATION
PL2470168T3 (pl) * 2009-08-26 2018-06-29 Bioelectron Technology Corporation Sposoby zapobiegania i leczenia niedokrwienia mózgu
KR101796340B1 (ko) 2011-02-18 2017-11-10 바이오링거스 아이피 엘엘씨 안정화된 활성제를 포함하는 생성물을 제조하는 방법 및 이를 포함하는 조성물
ES2683902T3 (es) 2011-06-14 2018-09-28 Hale Biopharma Ventures, Llc Administración de benzodiacepina
PT2919777T (pt) * 2012-11-13 2020-03-30 Invictus Biotechnology Pty Ltd Distribuição transmucosa de tocotrienol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010151348A1 (en) * 2009-06-25 2010-12-29 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
WO2011082355A1 (en) * 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
WO2011126998A1 (en) * 2010-04-06 2011-10-13 Edison Pharmaceuticals, Inc. Treatment of ataxia telangiectasia
WO2012068552A1 (en) * 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control

Also Published As

Publication number Publication date
CN104582700B (zh) 2021-01-05
BR112015010703A2 (pt) 2017-07-11
IL238727A0 (en) 2015-06-30
BR112015010703A8 (pt) 2018-08-14
US11331302B2 (en) 2022-05-17
JP6978392B2 (ja) 2021-12-08
PT2919777T (pt) 2020-03-30
PE20151518A1 (es) 2015-11-25
RU2015120181A (ru) 2017-01-10
PH12015501048A1 (en) 2015-07-27
KR20150082109A (ko) 2015-07-15
CA2891164A1 (en) 2014-05-22
MY177940A (en) 2020-09-28
BR112015010703B1 (pt) 2021-02-17
HK1207295A1 (en) 2016-01-29
CA2891164C (en) 2021-02-09
EP2919777A1 (en) 2015-09-23
JP2016503407A (ja) 2016-02-04
SG11201503640WA (en) 2015-06-29
JP2021008509A (ja) 2021-01-28
US20150265570A1 (en) 2015-09-24
IN2015DN04006A (cg-RX-API-DMAC7.html) 2015-10-02
EP2919777A4 (en) 2016-05-18
AU2013344817A1 (en) 2015-02-12
JP6460998B2 (ja) 2019-01-30
CN112451518A (zh) 2021-03-09
US10675265B2 (en) 2020-06-09
NZ628963A (en) 2017-02-24
DK2919777T3 (da) 2020-03-09
US20200246306A1 (en) 2020-08-06
EP2919777B1 (en) 2020-01-08
JP2019031504A (ja) 2019-02-28
WO2014075135A1 (en) 2014-05-22
CN112451518B (zh) 2025-02-21
ZA201504191B (en) 2016-11-30
PL2919777T3 (pl) 2020-07-13
ES2778065T3 (es) 2020-08-07
CN104582700A (zh) 2015-04-29

Similar Documents

Publication Publication Date Title
US11331302B2 (en) Transmucosal delivery of tocotrienol
CA2902603C (en) Compositions and methods for producing elevated and sustained ketosis
CN102088970B (zh) 用含槲皮素的组合物在制备改善肾功能的药物中的应用
EP2859896A1 (en) Pharmaceutical compositions for the treatment of muscular disorders
WO2002014477A2 (en) Bioavailable composition of natural and synthetic hca
TWI359667B (en) Formulation for oral administration having a healt
US20110117070A1 (en) Compositions and methods for treating headache
JP4355967B2 (ja) 医薬組成物
JP5584411B2 (ja) ホモシステイン低下用組成物
HK40048338A (zh) 生育三烯酚的经粘膜递送
HK1207295B (zh) 生育三烯酚的经粘膜递送
WO2003009840A1 (en) Composition comprising at least one lipase inhibitor and carnitine
JP5452042B2 (ja) 医薬組成物
CN116407502B (zh) 高epa含量的口服微乳及其制备方法和应用
CA3167614C (en) Nutritional compositions and methods containing a lignan and a methyl donor
EP3727359B1 (en) Treatment of fibrosis with inositol
JP4896531B2 (ja) 血中ＣｏＱ１０量を増加させる医薬組成物
CA2588491A1 (en) Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid profile

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: INVICTUS BIOTECHNOLOGY PTY LTD

Free format text: FORMER OWNER(S): GORDAGEN PHARMACEUTICALS PTY LTD